

OKLAHOMA BOARD OF NURSING
2915 N. Classen Boulevard, Suite 524
Oklahoma City, Oklahoma 73106

**CRNA Formulary Advisory Committee
Minutes-April 22, 2019**

The CRNA Formulary Advisory Council (“Council”) to the Oklahoma Board of Nursing (“Board”) met on April 22, 2019. Notice of the meeting was initially filed with the Secretary of State’s Office on December 11, 2018. Notice of the meeting was posted on the Oklahoma Board of Nursing web site not less than 24 hours prior to the meeting. A notice/agenda was also posted on the Cameron Building front entrance at 2915 North Classen Boulevard, Oklahoma City, Oklahoma, as well as the Board office at 2915 North Classen, Suite 524, at 4 PM on April 5, 2019 and not less than 24 hours prior to the meeting.

Place of Meeting: Basement Conference Room, Cameron Building

Time of Meeting: 3:30 PM

Members Present: Mark St Cyr, D.Ph.
Oklahoma Pharmacists Association

Lad Yates, MD
Oklahoma Society of Anesthesiologists

Thomas Tinker, MD
Oklahoma Society of Anesthesiologists

Victor Long, APRN-CRNA
Oklahoma Association of Nurse Anesthetists

Bruce Kennedy, APRN-CRNA
Oklahoma Association of Nurse Anesthetists

Members Absent: None

Board Representative: Jan Palovik, MS, APRN-CRNA

Staff Representatives: Jackye Ward, MS, RN
Gina Stafford, RN

Guest: None

1.0 Call to order: The meeting was called to order at 3:30 PM by Dr. Tinker, Chairperson.

1.1 Declaration of a quorum: A quorum was declared present.

2.0 Minutes of the previous meeting – April 23, 2018: The minutes were reviewed. A motion was made (V. Long) and seconded to approve the minutes of April 23, 2018.

Voting:

Yes: (5) B. Kennedy, V. Long, M. St Cyr, T. Tinker, L. Yates
No: (0)
Absent: (0)

Motion Carried.

3.0 Board of Nursing update (verbal reports requiring no action by Committee):

- 3.1 Proposed changes to the *Oklahoma Nursing Practice Act*:** J. Ward summarized proposed changes to the *Oklahoma Nursing Practice Act*.
- 3.2 Proposed changes to the *Oklahoma Board of Nursing Rules*:** J. Ward summarized proposed changes to the *Rules*.
- 3.3 New Enhanced Nurse Licensure Compact (NLC):** J. Ward provided an update regarding multistate licenses. The Agency has licensed over 5,000 RN/LPN applicants since the implementation of the NLC.
- 3.4 Formulary Advisory Council:** G. Stafford provided proposed changes to the *Exclusionary Formulary for Advanced Practice Registered Nurses with Prescriptive Authority*. The Formulary will move forward for Board approval in May.
- 3.5 Board approved guideline:** G. Stafford reviewed changes to the *Rapid Sequence Intubation Guideline for Registered Nurses*.
- 3.6 Updated regarding the passage of HR 6:** G. Stafford reviewed HR 6, known as the *Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act*. The Act was signed into law on October 24, 2018.
- 3.7 CRNA Formulary Advisory Council membership:** G. Stafford reported the appointment term for Dr. Lad Yates will expire 4/30/2019. The Oklahoma Medical Association will be contacted for the appointment of a representative.
- 3.8 Other:** no other reports

4.0 Review and committee recommendations on revisions to *CRNA Inclusionary Formulary*: Council members reviewed the DRAFT *CRNA Inclusionary Formulary*, #P-50A with proposed revisions. A list of new and updated monographs was provided to committee members. The proposed revisions include language changes to warnings, title change to 20:20 category, removal of two discontinued drugs, addition of two new drugs, correction to category 56:22.32, organize insulins to match the current edition of the *AHFS Drug Classification* and update to references. Additional revisions were discussed. These changes include removal of all warnings, references to warnings, asterisks and addition of one more drug. After discussion, it was moved (M. St Cyr) and seconded to recommend the following revisions to the *CRNA Inclusionary Formulary*, #P-50A to the Board for approval:

- Remove asterisks from the formulary, no need to identify which drugs are not in the print version on the *AHFS Drug Information*
- Remove all warnings and references to warnings
- Remove category 56:22.93
- Revise title for 20:00
- Identify Citrates
- Add three drugs:
 - Andexanet Alfa 20:28.92
 - Meloxicam 28:08.04.92
 - Insulin Glulisine 68:20.08.04
- Remove three drugs:
 - Metaraminol 12:12.12
 - Dextran 75 40:12
 - Insulin Zinc 68:20.08
- Update the reference for *AHFS Drug Information* to the current edition (2019)

Voting:

Yes: (5) B. Kennedy, V. Long, M. St Cyr, T. Tinker, L. Yates
 No: (0)
 Absent: (0)

Motion Carried.

5.0 Election of Chairperson and Vice Chairperson for 2020: It was moved (L. Yates) and seconded to appoint Dr. Tinker as Chairperson and to appoint Bruce Kennedy as Vice Chairperson for the next CRNA Formulary Advisory Council Meeting.

Voting:

Yes: (5) B. Kennedy, V. Long, M. St Cyr, T. Tinker, L. Yates
 No: (0)
 Absent: (0)

Motion Carried.

6.0 Date for next meeting: The members discussed possible dates and times for the next meeting.

6.1 Selected date and time for the next meeting will be Monday, April 20, 2020 at 3:30 PM.

Voting:

Yes: (5) B. Kennedy, V. Long, M. St Cyr, T. Tinker, L. Yates
 No: (0)

Absent: (0)

Motion Carried.

7.0 Adjournment: There being no further business, the meeting was adjourned at 4:31 PM.